Sandip Patel

Jan 9, 2025 | hmpgloballearningnetwork.com | Sandip Patel

In this interview, Sandip Patel, MD discusses the evolution of clinical pathways for non-small cell lung cancer (NSCLC), including the integration of perioperative strategies, the potential of immunotherapy in earlier stages, the role of artificial intelligence (AI) in treatment decision-making, and the impact of real-world data and emerging therapeutic targets. Please state your name, title, and any relevant clinical experience.

Jan 7, 2025 | onclive.com | Sandip Patel

CommentaryVideoJanuary 7, 2025Author(s):Sandip P. Patel, MD, discusses the potential role of antibody-drug conjugates in early-stage non–small cell lung cancer. “These antibody-drug conjugates [ADCs] have a variety of different targets, [such as] HER2, HER3, TROP2, and many others. Where ADCs could potentially play a role is at least two-fold in the early-stage setting.”Sandip P.

Dec 5, 2024 | onclive.com | Sandip Patel

CommentaryVideoDecember 5, 2024Author(s):Sandip P. Patel, MD, discusses the Immune Profile Score and how it may be used to inform decisions with immune checkpoint inhibitor therapy in solid tumors. “Similarly to how we think about genomically guided biomarkers helping improve drug development for targeted therapies, future iterations of IPS may inform which patients may benefit from a novel therapeutic strategy.”Sandip P.

Nov 1, 2024 | medium.com | Sandip Patel

Sandip Patel·Follow3 min read·--The solution starts from my thinking about others and my behaviour towards them. Mental health crises are currently the leading health problem in today’s world. As a result, many individuals may experience secondary issues such as addiction, anger, abusive behaviour, and a self-destructive attitude. We understand that mental health crises can arise from critical factors like loneliness, unkindness, and hateful behaviour.

Oct 29, 2024 | cancernetwork.com | Joshua K. Sabari |Sandip Patel

Putting Amivantamab Plus Lazertinib Into Practice Panelists discuss key takeaways from the analysis of long-term results, noting that these findings may influence their recommendations for first-line regimens in EGFR-mutant metastatic non–-small cell lung cancer. They highlight how they engage patients in discussions about treatment options, considering efficacy and safety, while addressing remaining unmet needs in this therapeutic area.